IPA (ImmunoPrecise Antibodies)

Press release: IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment. IPA has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for managing type 2 diabetes and obesity. Created using the Company's proprietary LENSᵃⁱ™ platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience. "LENSᵃⁱ's continued breakthroughs underscore the unparalleled power of our HYFT patterns," said Dr. Jennifer Bath, CEO of IPA. "These patterns, which only IPA possesses, are the key to unlocking unprecedented speed and precision in biologics research. LENSᵃⁱ is not just accelerating development—it's redefining the very process of therapeutic innovation." See the full release: https://lnkd.in/ePjYPnFm #GLP1 #Innovation #DrugDiscovery

Happy DNA Day! Today we celebrate the incredible marvel that is DNA—the code of life, nature’s ultimate data storage system. • Just one gram of DNA can theoretically hold up to approximately 455 exabytes of information—that’s more data than all the world’s libraries combined. • The DNA in a single human cell contains about 6 feet of tightly packed genetic code, folded perfectly to fit inside a microscopic nucleus. • Despite its simple four-letter alphabet, DNA encodes an unimaginably complex blueprint that orchestrates the development and function of every living organism. In biology, every layer—from DNA to proteins to entire pathways—is fundamentally interconnected. At IPA, AI-driven tools like LENSᵃⁱ™ connect and integrate the vast bio ecosystem, unifying diverse data types and sources into a comprehensive knowledge graph. By analyzing and interpreting immense volumes of biological data, LENSᵃⁱ reveals patterns and relationships within this intricate web, streamlining R&D and accelerating antibody therapeutic discovery. On this day, let’s marvel at the genius of the code of life—the molecule that carries the story of every living thing. #DNADay #TechBio #Antibodies #LifeSciences

𝗜𝘀 𝗶𝗺𝗺𝘂𝗻𝗼𝗴𝗲𝗻𝗶𝗰𝗶𝘁𝘆 𝗿𝗶𝘀𝗸 𝗹𝗶𝗺𝗶𝘁𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆’𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹? Early, accurate assessment is critical to advancing safe and effective therapeutics while avoiding costly late-stage failures. The LENSᵃⁱ™ Platform takes in silico immunogenicity assessment to the next level. Built on advanced AI and proprietary HYFT® technology, LENSᵃⁱ provides high-throughput, comprehensive risk analysis by combining HLA class II binding predictions with human proteome scanning. This platform is designed for seamless integration into your workflows, enabling you to screen, compare, and rank virtually limitless candidates—helping you to make faster, more confident decisions and accelerate the path from discovery to the clinic. 𝗞𝗲𝘆 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: • 𝗘𝗮𝗿𝗹𝘆, 𝗔𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: Detect immunogenic “hotspots” and prioritize candidates before investing in costly studies • 𝗡𝗼 𝗣𝗵𝘆𝘀𝗶𝗰𝗮𝗹 𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗱: Critical for assessing complex or hard-to-express proteins early and efficiently • 𝗦𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝗧𝗿𝗶𝗮𝗴𝗶𝗻𝗴: LENSᵃⁱ fits into your existing workflow, scaling easily allowing you to focus on most promising leads, minimizing wasted effort and expense • 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗛𝘂𝗺𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻: Optimize immunogenic profiles simultaneously • 𝗖𝗼𝗺𝗽𝗮𝘁𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝘄𝗶𝘁𝗵 𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗙𝗼𝗿𝗺𝗮𝘁𝘀: Including bispecific and multispecific antibodies • 𝗔𝗹𝗶𝗴𝗻𝗲𝗱 𝘄𝗶𝘁𝗵 𝗙𝗗𝗔 𝗮𝗻𝗱 𝗘𝗠𝗔 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲𝘀, including new FDA initiatives to phase out animal testing requirements with AI-based computational models Pair LENSᵃⁱ™ with our advanced in vivo discovery platform for an integrated solution that accelerates your pipeline. BioStrand (a subsidiary of IPA) #Immunogenicity #mAb #DrugDiscovery

IPA Collective Happy Hour at PEGS Boston. Kick-off your evening with IPA Collective. Connect with colleagues, dive into the latest breakthroughs, and celebrate where drug discovery is headed next. Wondering when and where AI and data make the biggest impact? Join us! 📍 Eddie Merlot’s, 505 Congress Street, Boston 🕔 Tues., May 13th, 5 – 7 PM EDT RSVP today. Limited spots available. https://bit.ly/42A6qv0 #PEGSBoston #AntibodyDiscovery #DrugDiscovery #InSilico #AI #IPACollective #BiotechNetworking

𝗙𝗗𝗔 𝗽𝗵𝗮𝘀𝗲𝘀 𝗼𝘂𝘁 𝗮𝗻𝗶𝗺𝗮𝗹 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 – 𝗢𝗿𝗴𝗮𝗻𝗼𝗶𝗱 𝗺𝗼𝗱𝗲𝗹𝘀 𝗻𝗼𝘄 𝗮𝗰𝗰𝗲𝗽𝘁𝗲𝗱 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝗳𝗼𝗿 𝗜𝗡𝗗 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀  Pivotal update, the FDA now accepts organoid data for IND submissions under its New Approach Methodologies (NAMs) framework, recognizing advanced, human-relevant tools—such as organoids, AI-driven modeling, and other NAMs—as valid options. 𝗣𝗿𝗲𝗽𝗮𝗿𝗶𝗻𝗴 𝘆𝗼𝘂𝗿 𝗹𝗮𝗯 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘀𝗵𝗶𝗳𝘁 𝘁𝗼 𝗼𝗿𝗴𝗮𝗻𝗼𝗶𝗱-𝗯𝗮𝘀𝗲𝗱 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵  IPA enables the shift to organoid-based systems with a portfolio of novel solutions designed to meet the highest performance standards:  - Proprietary WNT surrogate Fc-Fusion Protein supports WNT pathway activation with enhanced solubility, lower protein requirements, and outperforming traditionally used Wnt3a conditioned media. Engineered with the LRP-binding domain of DKK and a high-affinity Frizzled binder, it delivers reliable, reproducible performance in organoid systems. WNT surrogate Fc-Fusion Protein is renowned for its long-term stability at -80° C and as ready-to-use culture media at 4° C.  - Optimized Noggin Fc-Fusion Protein / R-spondin Fc-Fusion Protein conditioned media formulations.  - Research-grade, scalable matrices built for regulatory success. 𝗥𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲𝗱 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 𝗶𝗻 𝗼𝗿𝗴𝗮𝗻𝗼𝗶𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 IPA’s growth factor reagents have become a gold standard in organoid, tumoroid and organ-on-a-chip based research—cited in numerous peer-reviewed publications and trusted by leading cancer research centers and translational programs worldwide.  𝗜𝗡𝗗 𝗝𝘂𝗺𝗽𝘀𝘁𝗮𝗿𝘁 𝗢𝗳𝗳𝗲𝗿: 𝟮𝟬% 𝗼𝗳𝗳 𝗮𝗹𝗹 𝗼𝗿𝗴𝗮𝗻𝗼𝗶𝗱 𝗴𝗿𝗼𝘄𝘁𝗵 𝗳𝗮𝗰𝘁𝗼𝗿𝘀* • One time offer on new purchase orders for new and existing clients.  • Offer applies to a maximum of 3 units of one organoid growth factor type and size. • Email products@ipatherapeutics.com with promo code NAM2025 to get the offer. • Offer expires May 5th. *List price 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻. 𝗦𝗲𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀: https://lnkd.in/gzTMV7z7 #Organoids #WNTSurrogate #OncologyResearch

Press release: FDA recent decision to phase out animal testing requirement—highlighting alignment of IPA's strategic direction. The FDA’s announcement marks a significant advancement in regulatory modernization and aligns fully with ImmunoPrecise’s mission to revolutionize drug discovery and development processes through cutting-edge, human-relevant technologies, including its proprietary AI platform, LENSᵃⁱ™. With our proprietary LENSᵃⁱ platform, and full suite of integrated discovery and development tools, we’re opening doors to drug development that are not only more efficient—but also potentially safer and data-driven from the start. From safety and toxicity prediction to immunogenicity screening and drug efficacy knowledge graphs, it’s intelligence engineered for therapeutic impact and aligned with the FDA’s New Approach Methodologies (NAMs) framework to support regulatory compliance. See full release: https://lnkd.in/gm8chmtJ #AIforHealth #Antibodies #AI #DrugDiscovery #Biotech #TechBio

𝗪𝗵𝘆 𝘀𝗲𝗺𝗮𝗻𝘁𝗶𝗰 𝗥𝗔𝗚 𝗺𝗮𝘆 𝗯𝗲 𝘁𝗵𝗲 𝗺𝗶𝘀𝘀𝗶𝗻𝗴 𝗽𝗶𝗲𝗰𝗲 𝗶𝗻 𝘆𝗼𝘂𝗿 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 If you're using AI for drug discovery, you’ve likely hit these walls: - Outdated knowledge: Models trained on stale data miss critical breakthroughs - Non-traceable outputs: No way to trace how AI reached its conclusions - Biomedical ambiguity: Systems that can’t distinguish between "STAT3 the gene" and "STAT3 the pathway" Retrieval-Augmented Generation (RAG) helps by tethering AI to live data—but most implementations fall short for research. Here’s a key to success. 𝗧𝗵𝗲 𝗦𝗲𝗺𝗮𝗻𝘁𝗶𝗰 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 Our LENSᵃⁱ platform goes beyond basic RAG with: - Context-aware retrieval: Understands biological relationships, not just keywords (e.g., connects drug mechanisms to protein families) - Traceable outputs: Every suggestion links to source papers, clinical trials, or your proprietary data - Unified omics intelligence: Seamlessly integrates and queries structured data (genomics, proteomics, transcriptomics) and unstructured sources (literature, EHRs, etc) in a single AI-powered workflow. 𝗪𝗵𝘆 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿? Because drug discovery depends on relevance, reproducibility, and depth. We explore how RAG supports that—and what to watch out for—in our latest article: https://lnkd.in/eK2W7dDt #DrugDiscovery #RAG #LLM #BioStrandBlogs #Bioinformatics BioStrand (a subsidiary of IPA)

𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗶𝗲𝗱 - 𝗿𝗮𝗯𝗯𝗶𝘁 𝗺𝗔𝗯 𝘄𝗶𝘁𝗵 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆  With more than 𝟵𝟴% 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗿𝗮𝘁𝗲, our Rabbit B cell Select® platform consistently delivers high-affinity, diverse rabbit mAbs. These antibodies offer superior specificity and epitope diversity, enabling better recognition of challenging, complex and conserved targets - unlocking new therapeutic possibilities and accelerating the path to the clinic.  𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝘄𝗶𝘁𝗵 𝗿𝗮𝗯𝗯𝗶𝘁 𝗺𝗔𝗯 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗵𝗲𝗹𝗽𝘀 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗴𝗮𝗶𝗻: • 𝗕𝗲𝘁𝘁𝗲𝗿 𝗵𝗶𝘁𝘀, 𝗳𝗮𝘀𝘁𝗲𝗿 – Early-stage AI integration to identify hits with optimal characteristics, aimed at significantly reducing time and effort in later development stages.  • 𝗦𝗺𝗮𝗿𝘁𝗲𝗿 𝗿𝗮𝗻𝗸𝗶𝗻𝗴 – Simultaneous multiparameter analysis incorporated into leads ranking process such as developability and immunogenicity evaluation, to help minimize repeated iterations.  • 𝗥𝗮𝗽𝗶𝗱, 𝗻𝗼-𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹-𝗻𝗲𝗲𝗱𝗲𝗱 𝗲𝗽𝗶𝘁𝗼𝗽𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 – AI-driven epitope and paratope clustering & epitope mapping - performed entirely in silico, delivering results in just days, designed to drive cost and time efficiencies.  By combining cutting-edge AI technology and our deep expertise in rabbit mAb discovery, we fast-track the development of life-changing therapies—delivering them to patients sooner. 𝗥𝗲𝗮𝗱𝘆 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝘄𝗵𝗮𝘁’𝘀 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲? Let’s talk. https://lnkd.in/eTBRkN-m  #AntibodyDiscovery #RabbitmAbs #BioTech #DrugDevelopment #Biotherapeutics BioStrand (a subsidiary of IPA)

Fragmented data slowing down your drug discovery? It’s more common than you think. This week at #BioITWorld, we’re talking about the approximately 70% of researchers stuck wrangling incompatible datasets instead of driving innovation. The usual suspects: • Genomics, proteomics, and clinical data trapped in silos • Legacy systems that limit AI’s potential • Trial-and-error decisions caused by poor data alignment Here’s the shift: LENSᵃⁱ™, powered by BioStrand’s patented HYFT® technology, brings it all together by: • Offering a one-of-a-kind mult-omics fully integrated platform to uncover the unseen and expand the scope of your research • Stacking large language models that interpret biological context • Building knowledge graphs that uncover hidden protein–drug relationships “This isn’t just IT—it’s an R&D competitive edge.” – Dirk Van Hyfte, MD, Ph.D. — BioStrand`s Chief Technology Officer. We’re at Bio-IT World this week. Connect with Dirk to discuss how we can turn your data into real discovery: https://lnkd.in/geUC-WAA #BioIT2025 #AI #DrugDiscovery #MultiOmicsData BioStrand (a subsidiary of IPA)

Heading to Bio-IT World 2025 in Boston? Dirk Van Hyfte, MD, Ph.D., Head of Innovation, will be at BIO-IT from April 2-4, ready to chat about how LENSᵃⁱ™, powered by HYFTs, is making complex biological data work together for smarter #drugdiscovery. The challenge? Drug discovery depends on massive, disconnected datasets—genomics, proteomics, clinical data, literature. The solution? LENSᵃⁱ™ connects the dots: ✓ Faster AI-powered molecule design → Generative AI helps pinpoint novel candidates quicker. ✓ Seamless multi-modal integration → Genomics, proteomics, experimental data- finally in sync. ✓ Smarter workflows → AI-driven retrieval, RAG, and knowledge graphs deliver precision. ✓ Fewer costly experiments → Data-driven insights streamline decision-making. Looking for a better way to extract insights from your data? Let’s connect in Boston: https://lnkd.in/efHeZr-g #BioITWorld #Bioinformatics BioStrand (a subsidiary of IPA)